{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:11Z","timestamp":1786979891544,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010457","name":"Centre Hospitalier Universitaire de Bordeaux","doi-asserted-by":"publisher","award":["AOI"],"award-info":[{"award-number":["AOI"]}],"id":[{"id":"10.13039\/501100010457","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GIRCI-SOHO","award":["API-K 2016"],"award-info":[{"award-number":["API-K 2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07780-y","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:23:10Z","timestamp":1770596590000},"page":"4386-4394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective head-to-head comparison of [68Ga]Ga-RM2 PET\/CT and [68Ga]Ga-PSMA-617 PET\/CT in newly diagnosed patients with intermediate-risk localized prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Florian","family":"Perozziello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bladou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokrane","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lamare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Vimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Balamoutoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-9223","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Morgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"7780_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. [cited 2024 Apr 28];n\/a. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"7780_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.urology.2012.07.040","volume":"80","author":"AC Reese","year":"2012","unstructured":"Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National comprehensive cancer network prostate cancer risk classification system. Urology. 2012;80:1075\u20139. https:\/\/doi.org\/10.1016\/j.urology.2012.07.040.","journal-title":"Urology"},{"key":"7780_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18:79\u201392. https:\/\/doi.org\/10.1038\/s41585-020-00400-w.","journal-title":"Nat Rev Urol"},{"key":"7780_CR4","first-page":"229","volume":"30","author":"NA Serrano","year":"2016","unstructured":"Serrano NA, Anscher MS. Favorable vs unfavorable Intermediate-Risk prostate cancer: A review of the new classification system and its impact on treatment recommendations. Oncol (Williston Park). 2016;30:229\u201336.","journal-title":"Oncol (Williston Park)"},{"key":"7780_CR5","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2008.20.4669","volume":"27","author":"JR Stark","year":"2009","unstructured":"Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3\u2009+\u20094\u2009=\u20094\u2009+\u20093? J Clin Oncol. 2009;27:3459\u201364. https:\/\/doi.org\/10.1200\/JCO.2008.20.4669.","journal-title":"J Clin Oncol"},{"key":"7780_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3631-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7780_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Canc Netw"},{"key":"7780_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/pros.21434","volume":"72","author":"M Beer","year":"2012","unstructured":"Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318\u201325. https:\/\/doi.org\/10.1002\/pros.21434.","journal-title":"Prostate"},{"key":"7780_CR9","first-page":"1152","volume":"59","author":"R Markwalder","year":"1999","unstructured":"Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152\u20139.","journal-title":"Cancer Res"},{"key":"7780_CR10","first-page":"1139","volume":"8","author":"JC Reubi","year":"2002","unstructured":"Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer J-C, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6\u201314). Clin Cancer Res. 2002;8:1139\u201346.","journal-title":"Clin Cancer Res"},{"key":"7780_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/pros.22743","volume":"74","author":"M K\u00f6rner","year":"2014","unstructured":"K\u00f6rner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217\u201324. https:\/\/doi.org\/10.1002\/pros.22743.","journal-title":"Prostate"},{"key":"7780_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.122.263971","volume":"63","author":"H Duan","year":"2022","unstructured":"Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, et al. Correlation of 68 Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed Intermediate- or High-Risk prostate cancer. J Nucl Med. 2022;63:1829\u201335. https:\/\/doi.org\/10.2967\/jnumed.122.263971.","journal-title":"J Nucl Med"},{"key":"7780_CR13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263889","author":"R Schollhammer","year":"2022","unstructured":"Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, et al. Comparison of 68 Ga-PSMA-617 PET\/CT and 68 Ga-RM2 PET\/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.122.263889. jnumed.122.263889.","journal-title":"J Nucl Med"},{"key":"7780_CR14","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7780_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","volume":"76","author":"TBL Lam","year":"2019","unstructured":"Lam TBL, MacLennan S, Willemse P-PM, Mason MD, Plass K, Shepherd R, et al. EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study). Eur Urol. 2019;76:790\u2013813. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.020.","journal-title":"Eur Urol"},{"key":"7780_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.euo.2020.03.002","volume":"3","author":"F Preisser","year":"2020","unstructured":"Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, et al. Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol. 2020;3:270\u201380. https:\/\/doi.org\/10.1016\/j.euo.2020.03.002.","journal-title":"Eur Urol Oncol"},{"key":"7780_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN guidelines\u00ae insights: prostate Cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw Natl Compr Cancer Netw. 2024;22:140\u201350. https:\/\/doi.org\/10.6004\/jnccn.2024.0019.","journal-title":"J Natl Compr Cancer Netw Natl Compr Cancer Netw"},{"key":"7780_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272\u20137. https:\/\/doi.org\/10.1200\/JCO.2014.55.1192.","journal-title":"J Clin Oncol"},{"key":"7780_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1615869","volume":"377","author":"TJ Wilt","year":"2017","unstructured":"Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377:132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1615869.","journal-title":"N Engl J Med"},{"key":"7780_CR20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year outcomes after Monitoring, Surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"key":"7780_CR21","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s11255-024-04019-3","volume":"56","author":"AB Porcaro","year":"2024","unstructured":"Porcaro AB, Bianchi A, Panunzio A, Gallina S, Serafin E, Tafuri A, et al. Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course? Int Urol Nephrol. 2024;56:2597\u2013605. https:\/\/doi.org\/10.1007\/s11255-024-04019-3.","journal-title":"Int Urol Nephrol"},{"key":"7780_CR22","doi-asserted-by":"publisher","first-page":"650249","DOI":"10.3389\/fonc.2021.650249","volume":"11","author":"P Faviana","year":"2021","unstructured":"Faviana P, Boldrini L, Erba PA, Di Stefano I, Manassero F, Bartoletti R, et al. Gastrin-Releasing peptide receptor in low grade prostate cancer: can it be a better predictor than prostate-Specific membrane antigen? Front Oncol. 2021;11:650249. https:\/\/doi.org\/10.3389\/fonc.2021.650249.","journal-title":"Front Oncol"},{"key":"7780_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13550-019-0517-6","volume":"9","author":"R Schollhammer","year":"2019","unstructured":"Schollhammer R, De Clermont Gallerande H, Yacoub M, Quintyn Ranty M-L, Barthe N, Vimont D, et al. Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. EJNMMI Res. 2019;9:52. https:\/\/doi.org\/10.1186\/s13550-019-0517-6.","journal-title":"EJNMMI Res"},{"key":"7780_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12149-024-01978-6","volume":"38","author":"G Belge Bilgin","year":"2024","unstructured":"Belge Bilgin G, Bilgin C, Orscelik A, Burkett BJ, Thorpe MP, Johnson DR, et al. Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis. Ann Nucl Med. 2024;38:865\u201376. https:\/\/doi.org\/10.1007\/s12149-024-01978-6.","journal-title":"Ann Nucl Med"},{"key":"7780_CR25","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1111\/eci.70062","volume":"55","author":"A Imperiale","year":"2025","unstructured":"Imperiale A, Berti V, Cazzato RL, Mamulashvili Bessac D, Ressault A, Vaggelli L, et al. The evolving role of positron emission tomography in precision prostate cancer biopsy. Eur J Clin Invest. 2025;55:e70062. https:\/\/doi.org\/10.1111\/eci.70062.","journal-title":"Eur J Clin Invest"},{"key":"7780_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2967\/jnumed.122.264783","volume":"64","author":"H Duan","year":"2023","unstructured":"Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Aparici CM, et al. A pilot study of 68Ga-PSMA11 and 68Ga-RM2 PET\/MRI for evaluation of prostate cancer response to High-Intensity focused ultrasound therapy. J Nucl Med. 2023;64:592\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.264783.","journal-title":"J Nucl Med"},{"key":"7780_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.2967\/jnumed.122.264448","volume":"64","author":"H Duan","year":"2023","unstructured":"Duan H, Ghanouni P, Daniel B, Rosenberg J, Thong A, Kunder C, et al. A pilot study of 68Ga-PSMA11 and 68Ga-RM2 PET\/MRI for biopsy guidance in patients with suspected prostate cancer. J Nucl Med. 2023;64:744\u201350. https:\/\/doi.org\/10.2967\/jnumed.122.264448.","journal-title":"J Nucl Med"},{"key":"7780_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/RLU.0000000000005724","volume":"50","author":"Y Li","year":"2025","unstructured":"Li Y, Yang J, Xiao L, Zhou M, Gao X, Rominger A, et al. Using mpMRI, PSMA, and GRPR PET to assess focal therapy eligibility and plan treatment in Biopsy-proven Low-\/Intermediate-risk prostate cancer: A Whole-mount Pathology-based study. Clin Nucl Med. 2025;50:410\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000005724.","journal-title":"Clin Nucl Med"},{"key":"7780_CR29","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","volume":"33","author":"M Beheshti","year":"2023","unstructured":"Beheshti M, Taimen P, Kemppainen J, Jambor I, M\u00fcller A, Loidl W, et al. Value of 68Ga-labeled Bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study. Eur Radiol. 2023;33:472\u201382. https:\/\/doi.org\/10.1007\/s00330-022-08982-2.","journal-title":"Eur Radiol"},{"key":"7780_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/diagnostics15111358","volume":"15","author":"MJ Argow","year":"2025","unstructured":"Argow MJ, Hupfeld S, Schenke SA, Neumann S, Damm R, Vogt J, et al. Comparison of MpMRI and 68Ga-PSMA-PET\/CT in the assessment of the primary tumors in predominant Low-\/Intermediate-Risk prostate cancer. Diagnostics (Basel). 2025;15:1358. https:\/\/doi.org\/10.3390\/diagnostics15111358.","journal-title":"Diagnostics (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07780-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:43Z","timestamp":1779422923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07780-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7780"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07780-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Ide France 8.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a01 and 2.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"CM reports consulting activities for IRE Elit and research supports from IRE Elit and Life Molecular Imaging (LMI) outside this research support.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}